Author

J. Chang

Institutions: Fudan University, Fudan University Shanghai Cancer Center

Observed institutions: Fudan University, Fudan University Shanghai Cancer Center

ORCID: 0000-0002-1778-5823

Observed ORCID: 0000-0002-1778-5823

OpenAlex ID: A5083863098

OA02.05 Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study

2022 · Y.-L. Wu, Q. Zhou, et al. · Journal of Thoracic Oncology · 19

389P Updated efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion+ non-small cell lung cancer

2022 · Q. Zhou, Y-L. Wu, et al. · Annals of Oncology · 2

Works count: 2

Citation count: 21

H-index: 2

I10-index: 1